Abstract

BackgroundArtemisinin-based combination therapy (ACT) is a key strategy for global malaria elimination efforts. However, the development of artemisinin-resistant malaria parasites threatens progress and continued usage of oral artemisinin monotherapies (AMT) predisposes the selection of drug resistant strains. This is particularly a problem along the Myanmar/Thailand border. The artemisinin monotherapy replacement programme (AMTR) was established in 2012 to remove oral AMT from stocks in Myanmar, specifically by replacing oral AMT with quality-assured ACT and conducting behavioural change communication activities to the outlets dispensing anti-malarial medications. This study attempts to quantify the characteristics of outlet providers who continue to stock oral AMT despite these concerted efforts.MethodsA cross-sectional survey of all types of private sector outlets that were stocking anti-malarial drugs in 13 townships of Eastern Myanmar was implemented from July to August 2014. A total of 573 outlets were included. Bivariate and multivariable logistic regressions were conducted to assess outlet and provider-level characteristics associated with stocking oral AMT.ResultsIn total, 2939 outlets in Eastern Myanmar were screened for presence of any anti-malarial drugs in August 2014. The study found that 573 (19.5 %) had some kind of oral anti-malarial drug in stock at the time of survey and among them, 96 (16.8 %) stocked oral AMT. In bivariate analyses, compared to health care facilities, itinerant drug vendors, retailers and health workers were less likely to stock oral AMT (33.3 vs 12.9, 10.0, 8.1 %, OR = 0.30, 0.22, 0.18, respectively). Providers who cut blister pack or sell partial courses (40.6 vs 11.7 %, OR 5.18, CI 3.18–8.44) and those who based their stock decision on consumer demand (32.8 vs 12.1 %, OR 3.54, CI 2.21–5.63) were more likely to stock oAMT. Multivariate logistic regressions produced similar significant associations.ConclusionPrivate healthcare facilities and drug shops and providers who prioritize consumers’ demand instead of recommended practices were more likely to stock oral AMT. Malaria elimination strategies should include targeted interventions to effectively reach those outlets.

Highlights

  • Artemisinin-based combination therapy (ACT) is a key strategy for global malaria elimination efforts

  • This study found that compared to health care facilities and drug shop/pharmacies, itinerant drug vendors and health workers were five times less likely to stock oral

  • This hypothesis is supported in the current study by the three-fold increased odds of stocking oral artemisinin monotherapies (AMT) if decisions are reportedly driven by consumer demand and the fivefold increased odds of stocking oral AMT among providers who cut blister packs or sold partial courses

Read more

Summary

Introduction

Artemisinin-based combination therapy (ACT) is a key strategy for global malaria elimination efforts. The development of artemisinin-resistant malaria parasites threatens progress and continued usage of oral artemisinin monotherapies (AMT) predisposes the selection of drug resistant strains. This is a problem along the Myanmar/Thailand border. Artemisinin-based combination therapy (ACT) is considered an essential strategy in global malaria elimination efforts and the World Health Organization (WHO). In 2011, global plans for artemisinin resistance containment recommended phasing out oral AMT, along with three-tiered containment activities [6]. This was further intensified as an emergency response to artemisinin resistance in Greater Mekong Sub-region (GMS) in 2013 [7]. A study of private sector outlets in 2012 found that nearly 70 % of 747 retail outlets stocked oral AMT [10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call